{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:13:30Z","timestamp":1784178810561,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The World Health Organization classification (WHO-HAEM5) and the International Consensus Classification (ICC 2022) of myeloid neoplasms are based on the integration of clinical, morphologic, immunophenotypic, and genomic data. Flow cytometric immunophenotyping (FCIP) allows the identification, enumeration, and characterization of hematopoietic cells, and is therefore a\u00a0powerful tool in the diagnosis, classification, and monitoring of hematological neoplasms. The vast majority of flow cytometry (FCM) studies in chronic myeloid neoplasms focus on its role in myelodysplastic neoplasms (MDS). FCM can also be helpful for the assessment of myeloproliferative neoplasms (MPN) and MDS\/MPN, including the early detection of evolving myeloid or lymphoid blast crisis and the characterization of monocytic subsets. The classification of acute myeloid leukemia (AML) is primarily based on cytogenetic and molecular findings; however, FCIP is needed for subclassification of AML, not otherwise specified (NOS; ICC)\/AML defined by differentiation (WHO-HAEM5). The main role of FCM in AML remains in making a\u00a0rapid diagnosis and as a\u00a0tool for measurable residual disease monitoring. Machine learning and artificial intelligence approaches can be used to analyze and classify FCM data. This article, based on an invited lecture at the 106th Annual Meeting of the German Society of Pathology in 2023, reviews the role of FCM in the classification of myeloid neoplasms, including recent publications on the application of artificial intelligence.<\/jats:p>","DOI":"10.1007\/s00292-023-01272-8","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:02:32Z","timestamp":1700640152000},"page":"164-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The role of flow cytometry in the classification of myeloid disorders","Rolle der Durchflusszytometrie bei der Klassifikation myeloischer Neoplasien"],"prefix":"10.1007","volume":"44","author":[{"given":"Leonie","family":"Saft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"1272_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0RP et\u00a0al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228","journal-title":"Blood"},{"issue":"Suppl 1","key":"1272_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/ijlh.13548","volume":"43","author":"MC Bene","year":"2021","unstructured":"Bene\u00a0MC, Lacombe\u00a0F, Porwit\u00a0A (2021) Unsupervised flow cytometry analysis in hematological malignancies: a\u00a0new paradigm. Int J Lab Hematol 43(Suppl 1):54\u201364","journal-title":"Int J Lab Hematol"},{"key":"1272_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s11912-022-01252-w","volume":"24","author":"MC Bene","year":"2022","unstructured":"Bene\u00a0MC, Porwit\u00a0A (2022) Mixed phenotype\/lineage leukemia: has anything changed for 2021 on diagnosis, classification, and treatment? Curr Oncol Rep 24:1015\u20131022","journal-title":"Curr Oncol Rep"},{"key":"1272_CR4","doi-asserted-by":"crossref","unstructured":"Clichet V, Lebon D, Chapuis N et\u00a0al (2023) Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry. Haematologica","DOI":"10.3324\/haematol.2022.282370"},{"key":"1272_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cyto.b.22085","volume":"102","author":"H Fang","year":"2022","unstructured":"Fang\u00a0H, Wang\u00a0SA, Hu\u00a0S et\u00a0al (2022) Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry. Cytometry B Clin Cytom 102:283\u2013291","journal-title":"Cytometry B Clin Cytom"},{"key":"1272_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/cyto.b.21979","volume":"100","author":"M Gupta","year":"2021","unstructured":"Gupta\u00a0M, Jafari\u00a0K, Rajab\u00a0A et\u00a0al (2021) Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry. Cytometry B Clin Cytom 100:409\u2013420","journal-title":"Cytometry B Clin Cytom"},{"key":"1272_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood.2021012694","volume":"139","author":"A Henriques","year":"2022","unstructured":"Henriques\u00a0A, Mu\u00f1oz-Gonz\u00e1lez\u00a0JI, S\u00e1nchez-Mu\u00f1oz\u00a0L et al (2022) Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis. Blood 139:572\u2013583","journal-title":"Blood"},{"key":"1272_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ijlh.12787","volume":"40","author":"LL Herborg","year":"2018","unstructured":"Herborg\u00a0LL, Nederby\u00a0L, Hasselbalch\u00a0HC et\u00a0al (2018) Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: the utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry. Int J Lab Hematol 40:320\u2013325","journal-title":"Int J Lab Hematol"},{"key":"1272_CR9","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser\u00a0M, Freeman\u00a0SD, Ossenkoppele\u00a0GJ et\u00a0al (2021) 2021 Update on MRD in acute myeloid leukemia: a\u00a0consensus document from the European LeukemiaNet MRD Working Party. Blood 138:2753\u20132767","journal-title":"Blood"},{"key":"1272_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40272-021-00467-x","volume":"23","author":"LM Jones","year":"2021","unstructured":"Jones\u00a0LM, Tarlock\u00a0K, Cooper\u00a0T (2021) Targeted therapy in pediatric AML: an evolving landscape. Paediatr Drugs 23:485\u2013497","journal-title":"Paediatr Drugs"},{"key":"1272_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ajcp\/aqaa244","volume":"155","author":"K Kelemen","year":"2021","unstructured":"Kelemen\u00a0K, Saft\u00a0L, Craig\u00a0FE et al (2021) Eosinophilia\/Hypereosinophilia in the setting of reactive and idiopathic causes, well-defined myeloid or lymphoid leukemias, or germline disorders. Am J Clin Pathol 155:179\u2013210","journal-title":"Am J Clin Pathol"},{"key":"1272_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cyto.b.22105","volume":"104","author":"W Kern","year":"2023","unstructured":"Kern\u00a0W, Westers\u00a0TM, Bellos\u00a0F et\u00a0al (2023) Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group. Cytometry B Clin Cytom 104:51\u201365","journal-title":"Cytometry B Clin Cytom"},{"key":"1272_CR13","doi-asserted-by":"publisher","first-page":"103710","DOI":"10.1016\/j.critrevonc.2022.103710","volume":"175","author":"SK Khaldoyanidi","year":"2022","unstructured":"Khaldoyanidi\u00a0SK, Hindoyan\u00a0A, Stein\u00a0A et\u00a0al (2022) Leukemic stem cells as a\u00a0target for eliminating acute myeloid leukemia: Gaps in translational research. Crit Rev Oncol Hematol 175:103710","journal-title":"Crit Rev Oncol Hematol"},{"key":"1272_CR14","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury\u00a0JD, Solary\u00a0E, Abla\u00a0O et\u00a0al (2022) The 5th\u00a0edition of the world health organization classification of haematolymphoid tumours: myeloid and Histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719","journal-title":"Leukemia"},{"key":"1272_CR15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/cyto.a.24191","volume":"97","author":"SW Krause","year":"2020","unstructured":"Krause\u00a0SW (2020) On its way to primetime: artificial intelligence in flow cytometry diagnostics. Cytometry\u00a0A 97:990\u2013993","journal-title":"Cytometry A"},{"key":"1272_CR16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/ajcp\/aqaa281","volume":"156","author":"Y Li","year":"2021","unstructured":"Li\u00a0Y, Beck\u00a0RC, Moore\u00a0EM (2021) Pathogenic mutations and atypical flow cytometric findings characterize the majority of unclassifiable myelodysplastic\/myeloproliferative neoplasms. Am J Clin Pathol 156:634\u2013643","journal-title":"Am J Clin Pathol"},{"key":"1272_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cll.2023.04.005","volume":"43","author":"F Lucas","year":"2023","unstructured":"Lucas\u00a0F, Hergott\u00a0CB (2023) Advances in acute myeloid leukemia classification, prognostication and monitoring by flow cytometry. Clin Lab Med 43:377\u2013398","journal-title":"Clin Lab Med"},{"key":"1272_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/cyto.b.21946","volume":"100","author":"SGC Mestrum","year":"2021","unstructured":"Mestrum\u00a0SGC, De Wit\u00a0NCJ, Drent\u00a0RJM et\u00a0al (2021) Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS\/MPN diseases. Differences between MDS and MDS\/MPN. Cytometry B Clin Cytom 100:322\u2013330","journal-title":"Cytometry B Clin Cytom"},{"key":"1272_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/cyto.b.22030","volume":"104","author":"U Oelschlaegel","year":"2023","unstructured":"Oelschlaegel\u00a0U, Oelschlaeger\u00a0L, Von Bonin\u00a0M et\u00a0al (2023) Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: diagnostic power and prognostic impact. Cytometry B Clin Cytom 104:141\u2013150","journal-title":"Cytometry B Clin Cytom"},{"key":"1272_CR20","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood-2005-12-4916","volume":"108","author":"K Ogata","year":"2006","unstructured":"Ogata\u00a0K, Kishikawa\u00a0Y, Satoh\u00a0C et al (2006) Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 108:1037\u20131044","journal-title":"Blood"},{"key":"1272_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/cyto.b.22108","volume":"104","author":"A Porwit","year":"2023","unstructured":"Porwit\u00a0A, Bene\u00a0MC, Duetz\u00a0C et\u00a0al (2023) Multiparameter flow cytometry in the evaluation of myelodysplasia: analytical issues: recommendations from the European Leukemianet\/International Myelodysplastic Syndrome Flow Cytometry Working Group. Cytometry B Clin Cytom 104:27\u201350","journal-title":"Cytometry B Clin Cytom"},{"issue":"Suppl 1","key":"1272_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/ijlh.12368","volume":"37","author":"A Porwit","year":"2015","unstructured":"Porwit\u00a0A, Rajab\u00a0A (2015) Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10-color 14-antibody screening panel and 3\u2011tube extensive panel for detection of MDS-related features. Int J Lab Hematol 37(Suppl 1):133\u2013143","journal-title":"Int J Lab Hematol"},{"key":"1272_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ajcp\/aqaa208","volume":"155","author":"O Pozdnyakova","year":"2021","unstructured":"Pozdnyakova\u00a0O, Orazi\u00a0A, Kelemen\u00a0K et al (2021) Myeloid\/lymphoid neoplasms associated with Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2. Am J Clin Pathol 155:160\u2013178","journal-title":"Am J Clin Pathol"},{"key":"1272_CR24","doi-asserted-by":"crossref","unstructured":"Saft L, Kvasnicka HM, Boudova L et\u00a0al (2023) Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: a\u00a0workshop report with focus on novel entities and a\u00a0literature review including paediatric cases. Histopathology","DOI":"10.1111\/his.15021"},{"key":"1272_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12308-020-00394-9","volume":"13","author":"L Saft","year":"2020","unstructured":"Saft\u00a0L, Timar\u00a0B, Porwit\u00a0A (2020) Enumeration of CD34+blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification. J\u00a0Hematop 13:79\u201388","journal-title":"J Hematop"},{"key":"1272_CR26","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","volume":"125","author":"D Selimoglu-Buet","year":"2015","unstructured":"Selimoglu-Buet\u00a0D, Wagner-Ballon\u00a0O, Saada\u00a0V et al (2015) Characteristic repartition of monocyte subsets as a\u00a0diagnostic signature of chronic myelomonocytic leukemia. Blood 125:3618\u20133626","journal-title":"Blood"},{"key":"1272_CR27","unstructured":"Swerdlow SH (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. Int Agency Res Cancer Lyon"},{"key":"1272_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cyto.b.22044","volume":"104","author":"AA Van De Loosdrecht","year":"2023","unstructured":"Van De Loosdrecht\u00a0AA, Kern\u00a0W, Porwit\u00a0A et al (2023) Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A\u00a0report of the European LeukemiaNet International MDS-Flow Cytometry Working Group. Cytometry B Clin Cytom 104:77\u201386","journal-title":"Cytometry B Clin Cytom"},{"key":"1272_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cyto.b.22046","volume":"104","author":"VHJ Van Der Velden","year":"2023","unstructured":"Van Der Velden\u00a0VHJ, Preijers\u00a0F, Johansson\u00a0U et al (2023) Flow cytometric analysis of myelodysplasia: pre-analytical and technical issues-recommendations from the European Leukemianet. Cytometry B Clin Cytom 104:15\u201326","journal-title":"Cytometry B Clin Cytom"},{"key":"1272_CR30","doi-asserted-by":"publisher","first-page":"101019","DOI":"10.1016\/j.blre.2022.101019","volume":"58","author":"W Walter","year":"2023","unstructured":"Walter\u00a0W, Pohlkamp\u00a0C, Meggendorfer\u00a0M et\u00a0al (2023) Artificial intelligence in hematological diagnostics: Game changer or gadget? Blood Rev 58:101019","journal-title":"Blood Rev"}],"container-title":["Die Pathologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-023-01272-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-023-01272-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-023-01272-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T08:04:56Z","timestamp":1703145896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-023-01272-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":30,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1272"],"URL":"https:\/\/doi.org\/10.1007\/s00292-023-01272-8","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"24 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.\u00a0Saft declares that she has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All investigations on humans or human tissues described in this article were carried out with the approval of the responsible ethics committee, in accordance with national law and the Declaration of Helsinki from 1975 (in its current revised form). The investigations were carried out according to the specifications of the Central Ethics Committee of the Federal Medical Council.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}